Patent application number | Description | Published |
20090288788 | Pretreating cellulosic biomass - The present invention pertains to methods for pretreatment of cellulosic biomass for bioconversion into ethanol and other biofuels and wood-based chemicals, recycling of newsprint and other paper products, microfibrillation of cellulose for use as an additive in the food and cosmetic industries, manufacturing improved hardboard, and producing and improved “super” pulp while reducing chemical usage and spent liquor generation. In particular, the instant invention employs supercritical, critical or near critical fluids with and without polar cosolvents [critical fluid, SuperFluids or SFS] for the pretreatment of cellulosic biomass. | 11-26-2009 |
20100166806 | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency - The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors). | 07-01-2010 |
20100247620 | Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product - This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs. | 09-30-2010 |
20110287502 | METHODS AND APPARATUS FOR PROCESSING CELLULOSIC BIOMASS - Embodiments of the present invention are directed to apparatus and methods for the substantially continuous processing of cellulosic biomasses with a supercritical, critical or near critical fluid to produce ethanol, bio-fuels and high value end products. | 11-24-2011 |
20120309818 | CHRONIC INFLAMMATION AND TRANSPLANTATION - Embodiments of the present invention feature methods for treating inflammatory disease and transplantation characterized in that it includes: (i) the incubation of organs with one or more Bryostatin-1 derivatives under conditions which permits vascular exposure to these compounds prior to or immediately following organ ‘harvesting’, and (ii) intravenous, transdermal, intraperitoneal, intra-alveolar instillation of Bryostatin-1 in vivo during active disease, or during periods of disease remission and (iii) prophylactic administration of Bryostatin-1 to limit the development of GVHD. | 12-06-2012 |
20130122106 | DOSAGE FORM, AND METHODS OF MAKING AND USING THE SAME, TO PRODUCE IMMUNIZATION IN ANIMALS AND HUMANS - An embodiment of the present invention features a dosage form for administering antigen to cause an immune response in an animal or human subject in the nature of a vaccine. The dosage form comprises spheres having an effective amount of antigen to create an immune response and having an average diameter of 0.01 to 10.0 microns. The spheres comprise a polymer selected from the group consisting of poly(L-lactic acid), poly(D, L-lactic acid), poly(glycolic acid) and carboxylic acid and ester derivatives thereof, poly(fumaric anhydride) and poly(sebacic anhydride) and derivatives thereof. The spheres can be lyophilized and stored as a powder prior to use. The spheres can then be reconstituted and formulated in buffers with adjuvants. | 05-16-2013 |
20130156822 | DRUG DELIVERY SYSTEM AND METHOD FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASE - Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease. | 06-20-2013 |
20140080114 | METHODS, KITS AND COMPOSITIONS FOR INACTIVATION OF VIRAL AGENTS IN WHOLE BLOOD AND RED BLOOD CELL CONCENTRATES - The present invention is directed to methods, kits and compositions for inactivating viral agents in or on articles including blood based products and feature a light sensitive compound selected from the group consisting of hypericin, pseudohypericin and hypocrellin, and a group of light producing compounds comprising luciferase, luciferin and ATP. | 03-20-2014 |